MedTrace Logo

Impact of Estradiol Addback

NCT01862835 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2019-06-07

No results posted yet for this study

Summary

Repletion of testosterone (T) in older men drives Growth Hormone secretion after its aromatization to estradiol (E2) by potentiating endogenous GH drive.

Conditions

  • Normal Healthy Volunteers

Interventions

DRUG

Degarelix

DRUG

Testosterone

DRUG

Anastrozole

DRUG

Estrogen patch

Sponsors & Collaborators

Principal Investigators

  • Johannes Veldhuis, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2016-09-30
Completion
2018-12-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01862835 on ClinicalTrials.gov